MYC regulates ribosome biogenesis and mitochondrial gene expression programs through its interaction with host cell...

Area of Science:

• Oncology
• Molecular Biology
• Gene Regulation

Background:

• The oncoprotein transcription factor MYC drives malignancy and is a key target for cancer therapies.
• Understanding MYC co-factors is crucial for developing novel anti-cancer strategies.
• Host cell factor (HCF)-1 is a known MYC co-factor, but its specific role in MYC-driven tumorigenesis requires further investigation.

Purpose of the Study:

• To investigate the role of HCF-1 in MYC activity within human Burkitt lymphoma.
• To identify direct MYC/HCF-1 target genes and their functions.
• To evaluate the therapeutic potential of targeting the MYC-HCF-1 interaction.

Main Methods:

• ChIP-sequencing to identify direct MYC/HCF-1 targets.
• RNA-sequencing to analyze global gene expression changes.
• Metabolomic profiling to assess metabolic alterations.
• In vivo tumor growth assays in mouse models.

Main Results:

• Identified genes related to mitochondrial function and ribosome biogenesis as direct MYC/HCF-1 targets.
• Demonstrated that modulating the MYC-HCF-1 interaction impacts cell growth, metabolism, and gene expression.
• Showed that targeting the MYC-HCF-1 interaction inhibits tumor growth in vivo.

Conclusions:

• HCF-1 is a critical co-factor for MYC in Burkitt lymphoma.
• The MYC-HCF-1 interaction plays a significant role in regulating genes involved in mitochondrial function and ribosome biogenesis.
• HCF-1 represents a promising therapeutic target for novel anti-MYC cancer therapies.